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INTRODUCTION
Bone loss occurs frequently and rapidly following allogeneic stem cell transplantation (alloSCT). By 6 months post transplant~50% of patients will have osteoporosis or osteopenia at the femoral neck or lumbar spine. [1] [2] [3] This accelerated bone loss is associated with a high incidence of bone fractures in alloSCT recipients, with 8-10% of all patients developing a fracture within 3 years following transplantation. 2, 4, 5 The pathogenesis of bone loss following alloSCT is multifactorial. Patients frequently have low bone mineral density before alloSCT due to the cumulative effects of high-dose chemotherapy, prolonged immobility and vitamin D deficiency. 6 The conditioning regimen contributes to bone loss through induction of inflammatory cytokines. 7 Post transplant, bone loss is exacerbated by ovarian failure or testosterone deficiency and also by calcineurin inhibitors and glucocorticoids used in the prevention and treatment of GvHD. 1 The clinically significant bone loss post alloSCT emphasises the need for preventive intervention. Efforts to prevent bone loss using calcium supplementation, vitamin D replacement or hormonereplacement therapy alone have been ineffective. 1, 8 Bisphosphonates are antiresorptive agents that improve BMD in patients with osteoporosis. 9 We have previously reported that monthly IV pamidronate 90 mg before conditioning and continuing post alloSCT for 12 months reduced but did not prevent bone loss at the femoral neck or total hip compared with controls. 10 Zoledronic acid (ZA) is a bisphosphonate with~100-fold potency compared with pamidronate. 11, 12 Studies using ZA to prevent bone loss postalloSCT have been small in size or lacked appropriate controls. [13] [14] [15] [16] [17] [18] In this context, the Australasian Leukaemia and Lymphoma Group conducted a multicentre prospective study to examine the efficacy of pretransplant and individualised post-transplant ZA to prevent bone loss in patients undergoing alloSCT.
PATIENTS AND METHODS
Patients from eight hospitals in Australia and New Zealand were enrolled before alloSCT. All patients provided written informed consent. Adults (⩾18 years) were eligible for inclusion if they were planned to undergo alloSCT (irrespective of donor source, stem cell type or conditioning regimen), had estimated glomerular filtration rate ⩾ 30 ml/min and Eastern Cooperative Oncology Group performance status ⩽ 1. Patients with metabolic bone disorders, hypersensitivity to bisphosphonates or dental extraction within the previous 8 weeks were excluded.
Treatment protocol
This was a single-arm, prospective, phase II study designed to evaluate the efficacy of pretransplant and individualised post-transplant ZA to prevent femoral neck bone loss. The study protocol was approved by the human research ethics committee at each participating site, and the study was conducted in accordance with the Declaration of Helsinki (refer to Supplementary Information for study protocol). This study was prospectively registered on the Australian and New Zealand Clinical Trials Registry (study number: ACTRN12607000596404). All patients received ZA 4 mg IV 1 week before pretransplant conditioning. Femoral neck bone density was assessed by dual x-ray absorptiometry pretransplant and at days 100, 180, 270 and 365 post-alloSCT. Administration of post-transplant ZA was determined by an algorithm designed to identify patients with or at high risk of bone loss. Following each BMD assessment, patients were administered ZA 4 mg IV if they either had a reduction in BMD ⩾ 5% compared with baseline, or had or were anticipated to receive ⩾ 1 mg/kg per day prednisolone (or equivalent) for 2 weeks, or ⩾ 10 mg per day prednisolone for 6 weeks. The interval between each ZA dose was no shorter than 3 months.
Before transplant, cholecalciferol 2000 IU daily was given to patients with vitamin Do75 nmol/L until the first infusion of ZA. After the first ZA infusion, all patients received cholecalciferol 1000 IU and calcium carbonate 600 mg daily. Premenopausal women received hormonereplacement therapy with an oestrogen-containing preparation commencing 2 months post-alloSCT. Men were permitted to receive testosterone supplementation if serum testosterone levels were below the normal range 6 months post alloSCT. Glucocorticoid administration was not protocolised. In general, significant acute GVHD was treated with 2 mg/kg oral or IV prednisolone and tapered according to response. Cyclosporin was commenced at 3 mg/kg IV daily on day − 1, and changed to oral administration after resolution of mucositis. Duration of cyclosporin was tailored according to the presence of GVHD and disease relapse risk.
Historical controls
Data from 53 patients who did not receive post-transplant ZA were used as historical controls. These patients comprised the control arm of a previous randomised study of prophylactic pamidronate before and following alloSCT. 10 Briefly, patients were randomised to receive pamidronate 90 mg or no treatment, beginning pretransplant and continuing monthly post transplant for 12 months. All patients received calcium (1000 mg daily) and vitamin D (calcitriol 0.25 μg daily) supplementation, and female patients
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received hormone-replacement therapy with an oral oestrogen-containing preparation and progestogen.
Study end points
The primary end point was the change in femoral neck BMD at days 100 and 365 post-alloSCT compared with baseline. The secondary objective was a comparison of femoral neck BMD at days 100 and 365 with historical controls. Comparison of BMD between ZA-treated patients and the pamidronate arm of the study described above was performed as a post hoc exploratory analysis. Severity of acute GVHD (grades 1-4) and chronic GVHD (limited or extensive) were classified according to established criteria. 19, 20 Average glucocorticosteroid exposure was categorised as low (o10 mg per day prednisolone or equivalent), or high (⩾10 mg per day prednisolone). Conditioning regimens were categorised as either myeloablative or reduced intensity according to consensus definitions. 21 Subgroup analyses were planned according to indication for posttransplant ZA following the treatment algorithm: (1) patients who received ZA due to ⩾ 5% bone loss at femoral neck; (2) patients who received ZA because they met corticosteroid criteria; (3) patients who did not meet criteria for post-transplant ZA.
Statistical considerations
All patients who received at least one dose of ZA were included in the safety analysis. Patients who received ZA and were alive without relapse at days 100 and 365 were included in the efficacy analyses at those time points. Sample size estimation was based on data from our previous pamidronate study whereby the standard deviation of the change in bone density from baseline to day 100 was 5.4% and at day 365 was 6.6%. It was initially intended that 120 patients would be registered on the study, with 80 patients available for follow-up at day 365, giving a 95% confidence interval for the mean percentage change in bone density of ± 1% at day 100 and ± 1.5% at day 365, a level of precision regarded as clinically acceptable. This sample size target was not met due to slow recruitment. Comparisons between groups were assessed using t-tests and analysis of variance. Age, sex, conditioning regimen, baseline BMD, presence and severity of GVHD, steroid exposure and duration of calcineurin inhibitors were analysed for associations with change in BMD at day 100 and 365. Univariate associations with P o0.2 were included in multivariate models using forwards step-wise regression. All tests were two-sided with a significance level of 0.05. Unless otherwise stated results are presented as mean values ± s.d. Statistical analyses were performed using Stata MP (version 14.2; StataCorp, College Station, TX, USA).
RESULTS
Eighty-two patients were enrolled in the study (Figure 1 ). Two patients did not proceed to alloSCT, nine died or relapsed prior to day 100, and one patient was removed from the study. Seventy patients were included in the day 100 efficacy analysis ( Table 1) . The most common indications for alloSCT were acute myeloid (33%) and lymphoblastic (14%) leukaemia. The mean duration from diagnosis to transplant was 25.3 months. Forty patients (56%) received transplants from matched related donors and 30 patients (43%) from unrelated donors; 83% of patients received peripheral blood mobilised stem cells and 17% received bone marrow. Pretransplant conditioning regimens included cyclophosphamide with TBI (CyTBI) (29%), busulfan and cyclophosphamide (BuCy) (23%) and fludarabine and melphalan (27%). Twenty-six (37%) patients developed acute GVHD by day 100 post alloSCT, including 13 (19%) with grade 2-3 acute GVHD. No patient developed grade 4 acute GVHD. Forty-four (63%) patients had received glucocorticoids by day 100, with low or high exposure in 9 (13%) and 35 (50%) patients, respectively. Five patients died, relapsed or were lost to follow-up between day 100 and day 365 post-alloSCT. At day 365, 34 patients (52%) had active chronic GVHD, including 6 (9%) with extensive chronic GVHD. Thirty-eight (59%) patients had received glucocorticoids within the preceding 3 months, with low or high exposure in 20 (31%) and 18 (28%) patients respectively. There were no patients who developed a clinical bone fracture by day 365 post transplant.
Zoledronic acid administration All patients who proceeded to alloSCT received pretransplant ZA. At day 100 post alloSCT, 33 patients received ZA according to the risk-adapted algorithm, because of the presence of ⩾ 5% bone loss (19 patients) or glucocorticoid exposure (13) or both (1) (Figure 1) . Subsequently, 66 patients had BMD reassessment at day 180 post-alloSCT and 27 patients received ZA at this time point, including eight patients who had not qualified for ZA at day 100. At day 270, 65 patients underwent BMD assessment and 18 patients received ZA, including 1 patient who had not qualified for ZA at days 100 or 180. Overall, 42 (60%) patients received post transplant ZA between days 100 and 365 according to the risk-adapted algorithm, including 23 (33%) patients who received multiple doses. Patients received a median of two doses of ZA (range 1-4) including the baseline pretransplant dose.
There were no serious adverse events considered related to ZA. There were no recorded instances of symptomatic hypocalcaemia or mandibular or maxillary osteonecrosis. The most common grade 3-4 non-haematological adverse events including febrile neutropenia (49%), nausea (30%) and oral mucositis (28%) were not obviously related to ZA therapy.
Baseline BMD Before transplant, three patients (4%) had osteoporosis at the femoral neck and 22 patients (31%) had osteopenia. The prevalence of osteoporosis and osteopenia at the lumbar spine was 3% and 21%, respectively.
Day 100 change in BMD There was no statistically significant change in femoral neck BMD by day 100 post alloSCT compared with baseline (mean change − 2.6 ± 4.6%, 95% CI: − 6.6 to 1.4%) (Figure 2 ). Bone loss at day 100 varied according to severity of acute GVHD (P = 0.040), with the greatest bone loss observed in patients with grade 3 acute GVHD (−8.5 ± 11.2%). Patients with high corticosteroid exposure had greater bone loss compared with patients with low exposure, although this did not reach statistical significance (−3.6 ± 5.7% vs − 1.6 ± 3.1%; P = 0.073). Patients conditioned with BuCy had greater bone loss than patients who received CyTBI (−5.5 ± 5.5% Pre-and post transplant ZA in alloSCTvs − 1.4 ± 3.6%; P = 0.023) or other regimens (−5.5 ± 5.5% vs − 2.0 ± 4.4%; P = 0.034). This association was partially explained by differences in acute GVHD between patients who received BuCy compared with CyTBI or other regimens (P = 0.008). There were no significant associations between BMD change by day 100 and age, sex, duration of calcineurin inhibitors, duration of hospitalisation or baseline osteopenia/osteoporosis. In a multivariate model incorporating acute GVHD, intensity of glucocorticoid exposure and conditioning regimen, acute GVHD (P = 0.010) and BuCy conditioning (P = 0.036) remained significantly and independently associated with day 100 change in BMD.
Day 365 change in BMD There was a decrease in mean femoral neck BMD at day 365 post transplant compared with baseline (mean change − 2.9 ± 5.3%, 95% CI: − 4.2 to − 1.5%). There was no significant change between days 100 and 365. The greatest bone loss at day 365 was observed in patients who had a ⩾ 5% decrease in BMD at day 100 (mean change from baseline − 6.1 ± 3.3%) (Figure 3 ). There was no difference in bone loss from baseline to day 365 between patients who did not qualify for ZA compared with those who qualified for ZA based on steroid criteria alone (−2.1 ± 5.6% vs − 1.2 ± 5%; P = 0.843).
On univariate analysis, patients with extensive chronic GVHD had significantly greater femoral neck bone loss at day 365 compared with patients without chronic GVHD (−8.0 ± 3.6% vs − 1.2 ± 5.1%; P = 0.008). Patients with extensive chronic GVHD continued to lose bone between days 100 and 365 post alloSCT (mean change − 3.8 ± 5.4%), whereas BMD stabilised in patients with no or limited chronic GVHD (Figure 4 ). There was greater bone loss at day 365 in patients who received BuCy compared with CyTBI (−6.7 ± 3.6% vs − 0.7 ± 7.3%; P = 0.007). This association was partly explained by a difference in the rate of chronic GVHD between patients who received BuCy compared with CyTBI or other conditioning regimens (P = 0.002). There was a trend towards significance for the association between glucocorticoid exposure and bone loss at day 365 (high exposure − 4.7 ± 5.4% vs low exposure − 2.1 ± 5.1%; P = 0.07). There were no associations between day 365 BMD and age, sex, duration of calcineurin inhibitors or baseline osteoporosis/osteopenia. On multivariate analysis, acute GVHD (P = 0.012), chronic GVHD (P = 0.038) and conditioning regimen (P = 0.002) remained significantly and independently associated with femoral neck bone loss at day 365.
Comparison with historical controls and pamidronate-treated patients There were 53 untreated controls and 63 patients who received monthly pamidronate in the historical cohort. These patients were younger than ZA-treated patients, but there were no significant differences between groups with respect to sex, disease type or conditioning intensity (Table 1) . At days 100 and 365, femoral neck bone loss was significantly reduced in ZA-treated patients compared with untreated controls (−2.6 ± 4.6% vs − 6.0 ± 5.4%; P = 0.001 and − 2.9 ± 5.3% vs − 10.5 ± 6.8%; Po0.0001 respectively). The reduced bone loss in ZA-treated patients compared with controls at day 365 was observed in subgroups stratified by low glucocorticoid exposure (−2.1 ± 0.76% vs − 4.0 ± 2.5%; Po0.001) or high exposure (−4.7 ± 1.3% vs − 12.5 ± 2.0%; Po0.001). There was no significant difference in femoral neck bone loss between patients treated with risk-adapted ZA compared with monthly pamidronate at day 100 (−2.6 ± 4.6% vs − 3.1 ± 5.5%; P = 0.603) or day 365 (−2.9 ± 5.3% vs − 2.8 ± 6.9%; P = 0.959).
DISCUSSION
This study of ZA pre-and post alloSCT demonstrated several important findings. First, a single dose of ZA before alloSCT prevented significant femoral neck bone loss at day 100 in the overall study population, a time point characteristically associated with considerable bone loss. Bone loss at the femoral neck was also reduced compared with untreated control patients. The other N o p o s t -t r a n s p l a n t Z A P o s t -t a n s p l a n t Z A f o r s t e r o i d c r i t e r i a P o s t -t a n s p l a n t Z A Figure 4 . Change in femoral neck bone mineral density at day 365 according to chronic GVHD. Bone density stabilised between days 100 and 365 in patients with no or limited chronic GVHD, whereas patients with extensive chronic GVHD continued to lose bone up to day 365.
primary end point of this study was BMD status at day 365 post alloSCT. Using a risk-adapted algorithm to guide ZA administration, 60% of patients received ZA between days 100 and 365 post alloSCT. There was a mean loss of femoral neck bone density at day 365 compared with pretransplant, predominantly due to significant bone loss in patients with extensive chronic GVHD. Overall, however, mean femoral neck BMD was significantly improved compared with untreated historical controls at day 365. It is pertinent to note that the historical controls were younger than ZA-treated patients. Although this is likely to have understated the observed impact of ZA treatment since younger age is associated with improved BMD recovery post alloSCT, 22 we cannot exclude the possibility of other unforeseen bias that can only be reduced by a randomised trial design. There were also differences in the formulation of vitamin D supplementation (cholecalciferol versus calcitriol) and dose of calcium supplementation (600 mg elemental calcium versus 1000 mg) in the present study compared with the historical cohort; however, this is unlikely to have significantly impacted the results, given that previous randomised studies have failed to show a difference between calcitriol or cholecalciferol for the prevention of osteoporotic fractures. 23, 24 Patients with grade 3 acute GVHD (no patient developed grade 4) and those with high levels of corticosteroid exposure demonstrated ongoing bone loss at day 100 post alloSCT despite prophylactic ZA. In addition, patients with extensive chronic GVHD continued to lose bone between days 100 and 365 post alloSCT despite ZA according to the risk-adapted protocol. The degree of bone loss that we observed in patients with acute or extensive chronic GVHD approximates a 1 SD decrease in BMD, which is associated with a clinically significant increase in fracture risk. 25, 26 These observations confirm that acute and chronic GVHD remain significant risk factors for bone loss post alloSCT, and highlight the need for more effective strategies to preserve BMD in these high-risk patients. One approach is to increase the frequency of ZA in patients with steroid-dependent acute GVHD before day 100, or upon the development of chronic GVHD. Another approach is to use a more potent antiresorptive agent such as denosumab, an inhibitor of receptor activator of nuclear factor-κB ligand, which is superior to ZA in preserving femoral neck BMD in patients with malignant bone metastases or myeloma. 27, 28 Several studies have described the utility of ZA in improving BMD following alloSCT. Tauchmanova et al. 17 reported that ZA improved femoral neck and lumbar spine BMD in patients with established osteoporosis post-alloSCT. In another study, ZA every 3 months for 2 years increased BMD in patients with osteoporosis or osteopenia post alloSCT. However, there are few reports of prophylactic ZA to prevent bone loss post-alloSCT. Hari et al. 15 reported a small study of pre-and post transplant ZA in patients with osteopenia and observed improvement in femoral neck BMD compared with untreated controls at 12 months. 15 However, this study was limited by its small size with only 11 patients in the treatment arm. Our results therefore contribute to the literature in a significantly larger cohort of patients.
We were also able to compare the efficacy of a risk-adapted ZA approach to patients in a historical pamidronate-treated cohort. There was no difference in bone loss at day 100 between patients who received a single dose of pretransplant ZA compared with monthly pamidronate therapy. Furthermore, there was no difference in femoral neck BMD at day 365 in patients treated with the risk-adapted ZA protocol (median of 1 post-transplant dose of ZA) compared with monthly pamidronate (i.e. 12 infusions up to day 365). Both of these observations attest to the greater potency of ZA compared with pamidronate, which may facilitate a reduced frequency of bisphosphonates post alloSCT.
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A practical disadvantage or our risk-adapted strategy is the need for frequent BMD assessments between days 100 and 365 post-alloSCT, and an alternative approach could be considered.
Given that the key risk factors for BMD loss after day 100 include corticosteroid exposure and extensive chronic GVHD, 6 posttransplant ZA may be pre-emptively directed to patients with either of these risk factors. In our cohort, this algorithm would have a high level (93%) of agreement with the original protocol using serial BMD assessments. This approach has the advantage of being simple to implement, is cost-effective by removing the necessity for regular BMD assessments and should be investigated in a prospective trial. Alternatively, a clinical risk assessment tool (FRAX), which is able to assess the 10-year risk of bone fracture, has recently been developed and validated in the non-transplant setting. 29 If validated in alloSCT recipients, this may also be able to be incorporated in an algorithm to determine the need and intensity of post transplant ZA therapy.
In conclusion, a single dose of ZA pre-alloSCT prevents significant femoral neck bone loss at day 100 post alloSCT in the majority of patients. A risk-adapted algorithm is able to guide ZA administration from days 100 to 365 post transplant and reduce femoral neck bone loss compared with historical controls. Despite ZA therapy, patients with acute GVHD and extensive chronic GVHD are at high risk of bone loss and novel approaches to preserve bone should be investigated in these patients.
CONFLICT OF INTEREST
BB received payment for statistical services from the Australasian Leukaemia and Lymphoma Group (ALLG), and received consulting fees from Novartis for other unrelated work. AB has received honoraria from Novartis. The remaining authors declare no conflict of interest.
